Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Other Non-Current Liabilities: 2023-2025

Historic Other Non-Current Liabilities for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $4.4 million.

  • BioLineRx's Other Non-Current Liabilities fell 14.29% to $4.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.4 million, marking a year-over-year decrease of 14.29%. This contributed to the annual value of $1.7 million for FY2024, which is 85.83% down from last year.
  • BioLineRx's Other Non-Current Liabilities amounted to $4.4 million in Q2 2025, which was up 18.29% from $3.7 million recorded in Q1 2025.
  • Over the past 5 years, BioLineRx's Other Non-Current Liabilities peaked at $15.4 million during Q2 2023, and registered a low of $1.7 million during Q4 2024.
  • Its 3-year average for Other Non-Current Liabilities is $7.7 million, with a median of $6.3 million in 2024.
  • Data for BioLineRx's Other Non-Current Liabilities shows a maximum YoY plummeted of 85.83% (in 2024) over the last 5 years.
  • Over the past 3 years, BioLineRx's Other Non-Current Liabilities (Quarterly) stood at $11.9 million in 2023, then crashed by 85.83% to $1.7 million in 2024, then declined by 14.29% to $4.4 million in 2025.
  • Its Other Non-Current Liabilities stands at $4.4 million for Q2 2025, versus $3.7 million for Q1 2025 and $1.7 million for Q4 2024.